抗HER2/Neu抗体疗法通过阻断髓质衍生抑制细胞活动来抑制HER2+乳腺癌
Jae-Hyeog Choi1, Saegwang Park2, Xingguo Quan2
1New Drug Development Center, Daegu-Gyeongbuk Medical Innovation Foundation (K-MEDI hub), Daegu, Republic of Korea.
Oncology research and treatment
|October 17, 2025
概括
在HER2+乳腺癌模型中,抗neu抗体会降低髓质衍生抑制细胞 (MDSC) 和它们的免疫抑制功能. 这种减少与MDSC激活和迁移因子的减少有关,这表明MDSC是提高治疗疗效的治疗标.
科学领域:
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
- 癌症研究 癌症研究
背景情况:
- 骨髓原抑制细胞 (MDSC) 是瘤诱导免疫抑制的关键参与者,特别是在HER2/neu+乳腺癌中.
- MDSCs抑制了先天性和适应性免疫力,影响了抗瘤反应.
- 抗neu抗体对MDSCs的影响以前尚不清楚.
研究的目的:
- 研究抗neu抗体对MDSC种群的影响及其在HER2/neu+乳腺癌中的功能.
- 探索抗neu抗体介导的MDSC调制的潜在分子机制.
- 评估用于增强MDSC抑制的组合疗法.
主要方法:
- 携带HER2+ TUBO瘤的小鼠接受了抗neu抗体的治疗.
- 使用流细胞计和抑制试验评估了MDSC群体和免疫抑制功能.
- 基因表达分析 (RT2-PCR阵列,RT-PCR) 确定了与MDSC相关的关键因素. 还评估了与5-FU或龙酸的联合治疗.
主要成果:
- 抗neu抗体治疗在3天内显著降低了瘤和脏中的MDSC数量,单细胞MDSC显著减少.
- 减少了MDSCs的免疫抑制活性,同时减少了IL-1β,VEGF,CX3CL1和胺2,3-二氧化酶的表达.
- 与5-FU的联合治疗进一步抑制了MDSC和瘤相关巨细胞 (TAM),从而改善了瘤抑制.
结论:
- 通过抗neu抗体抑制瘤与MDSCs及其免疫抑制功能的减少有关.
- 抑制MDSC激活和迁移因素有助于这种效果.
- 在乳腺癌患者中,MDSCs代表了一个潜在的治疗目标,以提高像Herceptin这样的治疗方法的疗效.
更多相关视频
13:19Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
Published on: April 26, 2024
3.7K
13:59High-Content Screening Assay for the Identification of Antibody-Dependent Cellular Cytotoxicity Modifying Compounds
Published on: August 18, 2023
2.7K
相关概念视频
02:57Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
01:27Tumor Immunotherapy
1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
02:38Mitogens and the Cell Cycle
7.7K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.7K
02:34Inhibition of Cdk Activity
5.5K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K